In RA patients, the proportion of CD14+CD16+ monocytes is positively correlated with clinical parameters, such as CRP and DAS28-ESR, and is significantly decreased after a 12-week treatment with methotrexate (MTX), a gold standard, disease-modifying anti-rheumatic drug (DMARD) (34). This evidence concerns the gene FCGR3A and rheumatoid arthritis.